Theratechnologies Reports Financial Results and Business Updates for First Quarter 2023
Q1 2023 Consolidated Revenue Grew 7%, Supported by 9% Growth in EGRIFTA SV® Revenue and 5% Growth in Trogarzo® Revenue Revised Sudocetaxel Zendusortide Phase 1 Trial... | April 12, 2023
Source: marketscreener.com